Jessica Chubak to Humans
This is a "connection" page, showing publications Jessica Chubak has written about Humans.
Connection Strength
2.284
-
Positive Predictive Value of Symptoms for Early-Onset Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 2026 Aug 03; 35(8):1276-1282.
Score: 0.071
-
Association between Broad-Spectrum Antibiotic Use and Risk of Early-Onset Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 2026 Apr 01; 35(4):637-646.
Score: 0.069
-
Test-Retest Reliability and Mode Effects on Single-Item and Multi-Item Measures in a Survey of Adolescent and Young Adults with Cancer. J Adolesc Young Adult Oncol. 2026 Oct; 15(5):340-346.
Score: 0.068
-
Longitudinal Adherence to Screening for Colorectal, Cervical, and Lung Cancer in a US Consortium. J Gen Intern Med. 2026 05; 41(7):1761-1770.
Score: 0.067
-
Positive predictive value of cervical cancer screening results recommended for colposcopy by human papillomavirus vaccination status at 3 U.S. healthcare systems. Cancer Causes Control. 2025 Nov; 36(11):1549-1561.
Score: 0.066
-
Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning Ten Years after a Negative Colonoscopy, among Screen-Eligible Adults 76 to 85 Years Old. Cancer Epidemiol Biomarkers Prev. 2023 01 09; 32(1):37-45.
Score: 0.056
-
Informative Presence in Electronic Health Record Data: A Challenge in Implementing Study Exclusion Criteria. Epidemiology. 2023 Jan 01; 34(1):29-32.
Score: 0.054
-
Estimating Cancer Screening Sensitivity and Specificity Using Healthcare Utilization Data: Defining the Accuracy Assessment Interval. Cancer Epidemiol Biomarkers Prev. 2022 08 02; 31(8):1517-1520.
Score: 0.054
-
Noncancer comparators in cancer survivorship studies. Cancer. 2022 08 01; 128(15):2994.
Score: 0.053
-
Factors associated with employment discontinuation among older and working age survivors of oropharyngeal cancer. Head Neck. 2019 11; 41(11):3948-3959.
Score: 0.044
-
Risk of colon cancer recurrence in relation to diabetes. Cancer Causes Control. 2018 Nov; 29(11):1093-1103.
Score: 0.041
-
Financial difficulty, worry about affording care, and benefit finding in long-term survivors of cancer. Psychooncology. 2018 04; 27(4):1320-1326.
Score: 0.040
-
An Electronic Health Record-based Algorithm to Ascertain the Date of Second Breast Cancer Events. Med Care. 2017 12; 55(12):e81-e87.
Score: 0.039
-
Hepatocellular Carcinoma Surveillance Among Patients With Cirrhosis in a Population-based Integrated Health Care Delivery System. J Clin Gastroenterol. 2017 Aug; 51(7):650-655.
Score: 0.038
-
Pilot Study of Therapy Dog Visits for Inpatient Youth With Cancer. J Pediatr Oncol Nurs. 2017 Sep/Oct; 34(5):331-341.
Score: 0.038
-
Association of worry about cancer to benefit finding and functioning in long-term cancer survivors. Support Care Cancer. 2017 05; 25(5):1417-1422.
Score: 0.036
-
The Cancer Research Network: a platform for epidemiologic and health services research on cancer prevention, care, and outcomes in large, stable populations. Cancer Causes Control. 2016 11; 27(11):1315-1323.
Score: 0.036
-
Cancer survivors' experiences with insurance, finances, and employment: results from a multisite study. J Cancer Surviv. 2016 12; 10(6):1104-1111.
Score: 0.035
-
Aspirin for the Prevention of Cancer Incidence and Mortality: Systematic Evidence Reviews for the U.S. Preventive Services Task Force. Ann Intern Med. 2016 Jun 21; 164(12):814-25.
Score: 0.035
-
Defining and measuring adherence to cancer screening. J Med Screen. 2016 12; 23(4):179-185.
Score: 0.035
-
Time to Colonoscopy after Positive Fecal Blood Test in Four U.S. Health Care Systems. Cancer Epidemiol Biomarkers Prev. 2016 Feb; 25(2):344-50.
Score: 0.034
-
Animal-Assisted Activities: Results From a Survey of Top-Ranked Pediatric Oncology Hospitals. J Pediatr Oncol Nurs. 2016 07; 33(4):289-96.
Score: 0.034
-
Breast cancer recurrence in relation to antidepressant use. Cancer Causes Control. 2016 Jan; 27(1):125-36.
Score: 0.034
-
Psychometric investigation of benefit finding among long-term cancer survivors using the Medical Expenditure Panel Survey. Eur J Oncol Nurs. 2016 Feb; 20:31-5.
Score: 0.033
-
Assessing the effectiveness of a cancer screening test in the presence of another screening modality. J Med Screen. 2015 Jun; 22(2):69-75.
Score: 0.032
-
Perspectives of cancer survivors on the role of different healthcare providers in an integrated delivery system. J Cancer Surviv. 2014 Jun; 8(2):229-38.
Score: 0.030
-
Transitioning to independence and maintaining research careers in a new funding climate: american society of preventive oncology junior members interest group report. Cancer Epidemiol Biomarkers Prev. 2013 Nov; 22(11):2138-42.
Score: 0.029
-
Uptake and positive predictive value of fecal occult blood tests: A randomized controlled trial. Prev Med. 2013 Nov; 57(5):671-8.
Score: 0.029
-
Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival. J Natl Cancer Inst. 2013 Oct 02; 105(19):1456-62.
Score: 0.029
-
Time scale in follow-up studies: considering disease prognosis. Epidemiology. 2013 Jul; 24(4):628-9.
Score: 0.029
-
Measurement in comparative effectiveness research. Am J Prev Med. 2013 May; 44(5):513-9.
Score: 0.028
-
What can epidemiology contribute to comparative effectiveness research? J Epidemiol Community Health. 2013 Mar; 67(3):206-7.
Score: 0.028
-
Predictors of 1-year change in patient activation in older adults with diabetes mellitus and heart disease. J Am Geriatr Soc. 2012 Jul; 60(7):1316-21.
Score: 0.027
-
Administrative data algorithms to identify second breast cancer events following early-stage invasive breast cancer. J Natl Cancer Inst. 2012 Jun 20; 104(12):931-40.
Score: 0.026
-
Tradeoffs between accuracy measures for electronic health care data algorithms. J Clin Epidemiol. 2012 Mar; 65(3):343-349.e2.
Score: 0.026
-
Colorectal cancer risk in relation to antidepressant medication use. Int J Cancer. 2011 Jan 01; 128(1):227-32.
Score: 0.024
-
Cost of breast-related care in the year following false positive screening mammograms. Med Care. 2010 Sep; 48(9):815-20.
Score: 0.024
-
Colorectal cancer risk in relation to use of acid suppressive medications. Pharmacoepidemiol Drug Saf. 2009 Jul; 18(7):540-4.
Score: 0.022
-
Antidepressant medications and change in mammographic density in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2009 Feb; 18(2):676-9.
Score: 0.021
-
Breast cancer recurrence risk in relation to antidepressant use after diagnosis. Breast Cancer Res Treat. 2008 Nov; 112(1):123-32.
Score: 0.020
-
Endometrial cancer risk in estrogen users after switching to estrogen-progestin therapy. Cancer Causes Control. 2007 Nov; 18(9):1001-7.
Score: 0.019
-
Moderate-intensity exercise reduces the incidence of colds among postmenopausal women. Am J Med. 2006 Nov; 119(11):937-42.
Score: 0.018
-
Effect of exercise on bone mineral density and lean mass in postmenopausal women. Med Sci Sports Exerc. 2006 Jul; 38(7):1236-44.
Score: 0.018
-
Metastatic Recurrence Among Adolescents and Young Adults With Cancer. JAMA Oncol. 2026 01 01; 12(1):75-83.
Score: 0.017
-
Identifying Patterns of Late Effects With Latent Class Analysis Among Adolescent and Young Adult Thyroid Cancer Survivors in California and Utah. Cancer Med. 2025 Dec; 14(23):e71316.
Score: 0.017
-
Identifying clustering in patterns of late effects among survivors of adolescent and young adult Hodgkin lymphoma. JNCI Cancer Spectr. 2025 Nov 03; 9(6).
Score: 0.017
-
Incidence of chronic medical conditions among survivors of adolescent and young adult cancer compared to a population without cancer. Cancer. 2025 Oct 15; 131(20):e70125.
Score: 0.017
-
Associations between reproductive and menstrual factors and postmenopausal androgen concentrations. J Womens Health (Larchmt). 2005 Oct; 14(8):704-12.
Score: 0.017
-
Global impact of COVID-19 on organized CRC screening programs: lessons learned. Best Pract Res Clin Gastroenterol. 2026 Feb; 80:102047.
Score: 0.017
-
Trastuzumab therapy and new-onset hypertension in adolescents and young adults with breast cancer. Breast Cancer Res Treat. 2025 Aug; 213(1):81-92.
Score: 0.016
-
Delivering Guideline-Concordant Care for Patients With High-Risk HPV and Normal Cytologic Findings. JAMA Netw Open. 2025 Jan 02; 8(1):e2454969.
Score: 0.016
-
Optimal Stopping Ages for Colorectal Cancer Screening. JAMA Netw Open. 2024 Dec 02; 7(12):e2451715.
Score: 0.016
-
Associations between reproductive and menstrual factors and postmenopausal sex hormone concentrations. Cancer Epidemiol Biomarkers Prev. 2004 Aug; 13(8):1296-301.
Score: 0.015
-
Surveillance Colonoscopy Findings in Older Adults With a History of Colorectal Adenomas. JAMA Netw Open. 2024 Apr 01; 7(4):e244611.
Score: 0.015
-
Combining high quality data with rigorous methods: emulation of a target trial using electronic health records and a nested case-control design. BMJ. 2023 12 28; 383:e072346.
Score: 0.015
-
Timing of Colposcopy and Risk of Cervical Cancer. Obstet Gynecol. 2023 11 01; 142(5):1125-1134.
Score: 0.014
-
Evaluating Different Approaches for Calculating Adenoma Detection Rate: Is Screening Colonoscopy the Gold Standard? Gastroenterology. 2023 09; 165(3):784-787.e4.
Score: 0.014
-
Factors associated with timely colposcopy following an abnormal cervical cancer test result. Prev Med. 2022 11; 164:107307.
Score: 0.014
-
Evaluation of Harms Reporting in U.S. Cancer Screening Guidelines. Ann Intern Med. 2022 11; 175(11):1582-1590.
Score: 0.014
-
Gaps in the screening process for women diagnosed with cervical cancer in four diverse US health care settings. Cancer Med. 2023 Feb; 12(3):3705-3717.
Score: 0.014
-
Evaluating and Improving Cancer Screening Process Quality in a Multilevel Context: The PROSPR II Consortium Design and Research Agenda. Cancer Epidemiol Biomarkers Prev. 2022 08 02; 31(8):1521-1531.
Score: 0.013
-
Measured weight loss as a precursor to cancer diagnosis: retrospective cohort analysis of 43 302 primary care patients. J Cachexia Sarcopenia Muscle. 2022 Oct; 13(5):2492-2503.
Score: 0.013
-
Association of Physician Adenoma Detection Rates With Postcolonoscopy Colorectal Cancer. JAMA. 2022 06 07; 327(21):2114-2122.
Score: 0.013
-
Associations between molecular characteristics of colorectal serrated polyps and subsequent advanced colorectal neoplasia. Cancer Causes Control. 2020 Jul; 31(7):631-640.
Score: 0.012
-
Evaluating Screening Participation, Follow-up, and Outcomes for Breast, Cervical, and Colorectal Cancer in the PROSPR Consortium. J Natl Cancer Inst. 2020 03 01; 112(3):238-246.
Score: 0.011
-
An augmented estimation procedure for EHR-based association studies accounting for differential misclassification. J Am Med Inform Assoc. 2020 02 01; 27(2):244-253.
Score: 0.011
-
Changes in use of opioid therapy after colon cancer diagnosis: a population-based study. Cancer Causes Control. 2019 Dec; 30(12):1341-1350.
Score: 0.011
-
Long-term Risk of Colorectal Cancer and Related Death After Adenoma Removal in a Large, Community-based Population. Gastroenterology. 2020 03; 158(4):884-894.e5.
Score: 0.011
-
The association between colorectal sessile serrated adenomas/polyps and subsequent advanced colorectal neoplasia. Cancer Causes Control. 2019 Sep; 30(9):979-987.
Score: 0.011
-
Financial Incentives to Increase Colorectal Cancer Screening Uptake and Decrease Disparities: A Randomized Clinical Trial. JAMA Netw Open. 2019 07 03; 2(7):e196570.
Score: 0.011
-
Treatment patterns and survival differ between early-onset and late-onset colorectal cancer patients: the patient outcomes to advance learning network. Cancer Causes Control. 2019 Jul; 30(7):747-755.
Score: 0.011
-
CYP2D6-inhibiting medication use and inherited CYP2D6 variation in relation to adverse breast cancer outcomes after tamoxifen therapy. Cancer Causes Control. 2019 Jan; 30(1):103-112.
Score: 0.010
-
Diabetes Treatments and Risks of Adverse Breast Cancer Outcomes among Early-Stage Breast Cancer Patients: A SEER-Medicare Analysis. Cancer Res. 2017 11 01; 77(21):6033-6041.
Score: 0.010
-
Use of Antihypertensive Medications and Risk of Adverse Breast Cancer Outcomes in a SEER-Medicare Population. Cancer Epidemiol Biomarkers Prev. 2017 11; 26(11):1603-1610.
Score: 0.010
-
A centralized mailed program with stepped increases of support increases time in compliance with colorectal cancer screening guidelines over 5 years: A randomized trial. Cancer. 2017 Nov 15; 123(22):4472-4480.
Score: 0.010
-
Reproductive factors and risk of colorectal polyps in a colonoscopy-based study in western Washington State. Cancer Causes Control. 2017 03; 28(3):241-246.
Score: 0.009
-
Influence of Age and Comorbidity on Colorectal Cancer Screening in the Elderly. Am J Prev Med. 2016 09; 51(3):e67-75.
Score: 0.009
-
Association Between Primary Care Visits and Colorectal Cancer Screening Outcomes in the Era of Population Health Outreach. J Gen Intern Med. 2016 10; 31(10):1190-7.
Score: 0.009
-
Racial/Ethnic Disparities in Colorectal Cancer Screening Across Healthcare Systems. Am J Prev Med. 2016 10; 51(4):e107-15.
Score: 0.009
-
Colorectal Cancer Screening Rates Increased after Exposure to the Patient-Centered Medical Home (PCMH). J Am Board Fam Med. 2016 Mar-Apr; 29(2):191-200.
Score: 0.009
-
Statistical Methods for Estimating the Cumulative Risk of Screening Mammography Outcomes. Cancer Epidemiol Biomarkers Prev. 2016 Mar; 25(3):513-20.
Score: 0.009
-
Enhancing Breast Cancer Recurrence Algorithms Through Selective Use of Medical Record Data. J Natl Cancer Inst. 2016 Mar; 108(3).
Score: 0.008
-
Impact of continued mailed fecal tests in the patient-centered medical home: Year 3 of the Systems of Support to Increase Colon Cancer Screening and Follow-Up randomized trial. Cancer. 2016 Jan 15; 122(2):312-21.
Score: 0.008
-
An economic evaluation of colorectal cancer screening in primary care practice. Am J Prev Med. 2015 Jun; 48(6):714-21.
Score: 0.008
-
Do depressed newly diagnosed cancer patients differentially benefit from nurse navigation? Gen Hosp Psychiatry. 2015 May-Jun; 37(3):236-9.
Score: 0.008
-
Cancer Risk Awareness and Concern among Women with a Family History of Breast or Ovarian Cancer. Behav Med. 2016; 42(1):18-28.
Score: 0.008
-
Results of nurse navigator follow-up after positive colorectal cancer screening test: a randomized trial. J Am Board Fam Med. 2014 Nov-Dec; 27(6):789-95.
Score: 0.008
-
Longitudinal predictors of colorectal cancer screening among participants in a randomized controlled trial. Prev Med. 2014 Sep; 66:123-30.
Score: 0.008
-
The colorectal cancer screening process in community settings: a conceptual model for the population-based research optimizing screening through personalized regimens consortium. Cancer Epidemiol Biomarkers Prev. 2014 Jul; 23(7):1147-58.
Score: 0.008
-
Time to screening in the systems of support to increase colorectal cancer screening trial. Cancer Epidemiol Biomarkers Prev. 2014 Aug; 23(8):1683-8.
Score: 0.008
-
Patterns of colorectal cancer screening uptake in newly eligible men and women. Cancer Epidemiol Biomarkers Prev. 2014 Jul; 23(7):1230-7.
Score: 0.008
-
Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer. Breast Cancer Res Treat. 2014 Apr; 144(2):405-16.
Score: 0.008
-
Nurse navigators in early cancer care: a randomized, controlled trial. J Clin Oncol. 2014 Jan 01; 32(1):12-8.
Score: 0.007
-
Psychological distress after a positive fecal occult blood test result among members of an integrated healthcare delivery system. Cancer Epidemiol Biomarkers Prev. 2014 Jan; 23(1):154-9.
Score: 0.007
-
Frequent antibiotic use and second breast cancer events. Cancer Epidemiol Biomarkers Prev. 2013 Sep; 22(9):1588-99.
Score: 0.007
-
Risk of non-Hodgkin lymphoma in relation to tricyclic antidepressant use. Ann Epidemiol. 2013 Jun; 23(6):349-54.
Score: 0.007
-
An automated intervention with stepped increases in support to increase uptake of colorectal cancer screening: a randomized trial. Ann Intern Med. 2013 Mar 05; 158(5 Pt 1):301-11.
Score: 0.007
-
Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average-risk adults: a nested case-control study. Ann Intern Med. 2013 Mar 05; 158(5 Pt 1):312-20.
Score: 0.007
-
Cancer research network: using integrated healthcare delivery systems as platforms for cancer survivorship research. J Cancer Surviv. 2013 Mar; 7(1):55-62.
Score: 0.007
-
Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer. J Oncol Pract. 2012 Nov; 8(6):e149-57.
Score: 0.007
-
Prophylactic oophorectomy rates in relation to a guideline update on referral to genetic counseling. Gynecol Oncol. 2012 Aug; 126(2):229-35.
Score: 0.007
-
Nonparticipation in a population-based trial to increase colorectal cancer screening. Am J Prev Med. 2012 Apr; 42(4):390-7.
Score: 0.007
-
Patient-reported care coordination: associations with primary care continuity and specialty care use. Ann Fam Med. 2011 Jul-Aug; 9(4):323-9.
Score: 0.006
-
Systems of support to increase colorectal cancer screening and follow-up rates (SOS): design, challenges, and baseline characteristics of trial participants. Contemp Clin Trials. 2010 Nov; 31(6):589-603.
Score: 0.006
-
Referral, receipt, and completion of chemotherapy in patients with early-stage breast cancer older than 65 years and at high risk of breast cancer recurrence. J Clin Oncol. 2009 Sep 20; 27(27):4508-14.
Score: 0.005
-
Identifying key questions to advance research and practice in cancer survivorship follow-up care: a report from the ASPO Survivorship Interest Group. Cancer Epidemiol Biomarkers Prev. 2009 Jul; 18(7):2152-4.
Score: 0.005
-
Effect of exercise on serum sex hormones in men: a 12-month randomized clinical trial. Med Sci Sports Exerc. 2008 Feb; 40(2):223-33.
Score: 0.005
-
Effect of a 12-month randomized clinical trial of exercise on serum prolactin concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2007 May; 16(5):895-9.
Score: 0.005
-
Effects of an exercise intervention on other health behaviors in overweight/obese post-menopausal women. Contemp Clin Trials. 2007 Jul; 28(4):472-81.
Score: 0.005
-
Serum lipoproteins in overweight/obese postmenopausal women: a one-year exercise trial. Med Sci Sports Exerc. 2006 Feb; 38(2):231-9.
Score: 0.004
-
Effect of exercise on serum androgens in postmenopausal women: a 12-month randomized clinical trial. Cancer Epidemiol Biomarkers Prev. 2004 Jul; 13(7):1099-105.
Score: 0.004
-
The effect of CYP19 and COMT polymorphisms on exercise-induced fat loss in postmenopausal women. Obes Res. 2004 Jun; 12(6):972-81.
Score: 0.004
-
Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2004 Jan; 13(1):94-101.
Score: 0.004